Skip to main content
Premium Trial:

Request an Annual Quote

AxCell Biosciences

Premium

The US Patent and Trademark office has awarded AxCell Biosciences US patent 6,309,820 entitled “Polypeptides Having a Functional Domain of Interest and Methods of Identifying and Using Same.” The patent, with 9 claims, covers the company’s method for identifying SH3 domain-containing proteins from human cDNA expression libraries, and is the first patent awarded for AxCell’s Cloning of Ligand Targets proteomics technology. In previous studies, researchers have associated proteins containing SH3 domains with cancer, diabetes, and diseases of the central nervous system. “This technology permits the use of ligands — small peptide sequences that bind to larger domain units within proteins — to discover new domains and ultimately new proteins that may be useful as drug targets,” said AxCell CEO John Rodwell in a statement. AxCell is currently building its ProChart database of protein-protein interactions involved in cell signaling.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.